Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Clin Pharmacol. 2020 Sep 22;61(3):378–387. doi: 10.1002/jcph.1743

Table 2.

Final model and bootstrap analysis1

Final Model Bootstrap Analysis2
Point Estimate RSE (%) 95% CI CV (%) 2.5th percentile Median 97.5th percentile
CL (L/h) for a 3.4-kg neonate 0.038 11.9 0.03, 0.05 0.03 0.037 0.05
V (L/3.4 kg) 3.83 4.73 3.48, 4.18 3.50 3.83 4.21
TM50 on CL (days) 5.91 31.5 2.26, 9.56 1.84 5.96 12.30
RRT3 on CL 6.23 4.35 5.70, 6.76 4.71 7.97 17.60
Interindividual variability on CL 0.15 34.8 0.05, 0.25 38.9 0.04 0.14 0.24
Interindividual variability on V 0.07 24.3 0.04, 0.10 26.2 0.03 0.07 0.10
Residual variability4 0.01 26.8 0.006, 0.02 10.9 0.005 0.01 0.02
1

Parameter estimates are for a 3.4–kg neonate

2

Bootstrap successful in 100% of runs

3

Excluding slow continuous ultrafiltration

4

Proportional error

CL (L/h)=0.038*(WT/3.4)0.75*(AGE/(5.91+AGE)) *6.23 (if on RRT)

V (L)=3.83*(WT/3.4)

ALB: albumin, CL: clearance, CV: coefficient of variation, RRT: renal replacement therapy, RSE: relative standard error, TM50: age at which clearance reaches 50% of adult values, V: volume of distribution